Navigation Links
Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R)
Date:12/17/2007

Presentations Provide New Insights into Treatment Impact, Node-Positive

Breast Cancer, Measuring ER/PR Scores

REDWOOD CITY, Calif., Dec. 17 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from multiple studies reinforcing the clinical utility of the company's Oncotype DX(R), a multi-gene expression test to predict the likelihood of recurrence and the likelihood of chemotherapy benefit for a large portion of early-stage breast cancer patients. This research was presented at the 30th Annual San Antonio Breast Cancer Symposium, December 13-15.

"The extensive body of research on Oncotype DX, including data presented in San Antonio this week, along with its recent inclusion in ASCO treatment guidelines, supports the use of Oncotype DX in treatment planning for women with early-stage estrogen receptor-positive breast cancer," said Lori J. Goldstein, M.D., Director of the Breast Evaluation Center at Fox Chase Cancer Center in Philadelphia, Pennsylvania, and author of two Oncotype DX studies.

Eight studies presented at the San Antonio Breast Cancer Symposium evaluated Oncotype DX, including its use in estrogen receptor-positive, node- positive breast cancer; the test's impact on treatment selection and patient satisfaction; reporting of quantitative ER and PR scores within the Oncotype DX report; and a comparison between the Oncotype DX Recurrence Score(TM) and Adjuvant Online, among other presentations.

Positive Results in Node-Positive Disease

* An oral presentation by the Southwest Oncology Group (SWOG) on

Thursday, December 13 reported positive results for the Oncotype DX

Recurrence Score result in early-stage estrogen receptor
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
3. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
4. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
5. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
6. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
7. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
10. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
11. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , July 2, 2015  The Green Exchange, ... the world,s first HIPAA compliant mobile app that connects ... farm-to-table fresh medical marijuana, announced today that their service ... Unlike Eaze, Meadow and more than half a dozen ... last year, Loud Cannabis is unique in that it ...
(Date:7/2/2015)... 2015   Decision Resources Group finds ... less frequent dosing as the highest unmet need ... burden on both patients and providers associated with ... injections, which are the current standard of care. ... is in development for dosing every two to ...
(Date:7/2/2015)... June 25, 2015 ... announced the addition of the "2015 ... Global Challenges, Emerging Technologies, Competitive Landscape" ... New Frontiers in Clinical Chemistry and Immunodiagnostics: ... a new seven-country strategic analysis of major ...
Breaking Medicine Technology:New Cannabis Delivery App Gets Product to Patient in Under 7 Minutes 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 2Retinal Specialists Indicate Strong Desire for DME Therapies Which Induce Greater Vision Gains or are Administered Less Frequently Than Currently Approved Anti-VEGF Therapies 3New Frontiers in 2015 Global Clinical Chemistry and Immunodiagnostics Market: Challenges, Emerging Technologies, Competitive Landscape 2
... ... tumors, SEATTLE, ... for advanced, metastatic prostate cancer has been,androgen-deprivation therapy. That is, the ... via,surgical castration (orchiectomy) or medical castration with,testosterone-blocking drugs. While such therapy ...
... Cell Lung Cancer, WASHINGTON, June 2 Today, ... from the pivotal Phase,III First Line in Lung Cancer ... Society of Clinical Oncology (ASCO), showed a,significant increase in ... non-small cell lung cancer (NSCLC)., "This is very ...
Cached Medicine Technology:Research Explains How Advanced Prostate Cancer Becomes Resistant to Androgen-Deprivation Therapy 2Research Explains How Advanced Prostate Cancer Becomes Resistant to Androgen-Deprivation Therapy 3Research Explains How Advanced Prostate Cancer Becomes Resistant to Androgen-Deprivation Therapy 4Lung Cancer Alliance Hails Announcement of New Erbitux(R) Data 2
(Date:7/4/2015)... ... ... hacker gains access to someone’s email account, it can lead to all sorts of trouble, ... FTC issued a scam alert about a social engineering scam which cons a target ... by the hacker. All they have to do is click for a password reset ...
(Date:7/3/2015)... (PRWEB) , ... July 03, 2015 , ... ... Dori Friend opened registration for a new SEO training system called "Page ... guide for organic traffic generation has received glowing reviews from several well-known marketers. ...
(Date:7/3/2015)... ... July 03, 2015 , ... B. E. Smith, the ... to lead a national president recruitment for Regional Care, Inc. in ... B. E. Smith has recently placed more than 1,000 healthcare executives into organizations. ...
(Date:7/3/2015)... MO (PRWEB) , ... July 03, 2015 , ... Talcum ... website to replace their existing Talcum Powder Cancer Lawsuit Center website. Just as the ... talcum powder lawsuit news , offering timely lawsuit updates and ovarian cancer warning information. ...
(Date:7/3/2015)... ... July 03, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... says will reveal biblical truth and expose popular lies regarding proper relationships according to ... Have Sex”, immediately goes into the core of the subject by explaining why certain ...
Breaking Medicine News(10 mins):Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 2Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 3Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 4Health News:Page One Engine - Review Of Dori Friend's SEO Training Course Released 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 3Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3Health News:Yisrayl Hawkins Explains What the Bible Really Says about Sex in New Publication This Week 2
... its new expansion of the Pharmacogenomics Research Network (PGRN), ... Children,s Research Hospital a prestigious grant to focus on ... million grant is titled "PAAR4KidsPharmacogenomics of Anticancer Agents Research ... for 10 years. But now, we will be the ...
... Clinical trials in a variety of areas within interventional ... will directly affect the way that people with cardiovascular ... presented exclusively at TCT, will lead to new treatments ... Among the topics being covered are stenting in the ...
... being fed a poor diet of biscuits, ice-cream and soft ... in the journal Nutrition & Dietetics found some ... sugar foods, despite health authorities recommending exclusive breastfeeding to six ... tracked 587 women from two Perth maternity hospitals through regular ...
... The United States must focus on conserving the use ... from rapidly rising rates of antibiotic-resistant infections, according to ... nation,s supply of antibiotics is being depleted by resistance, ... that they no longer respond to widely-used treatments. Most ...
... pilot study suggests the hallucinogen psilocybin may be feasible ... and anxiety, with promising effects on mood, according to ... the January 2011 print issue of Archives of ... "In recent years, there has been a growing awareness ...
... and about one-fifth of fathers in the United Kingdom appear ... and 12th year of age, with the highest rates in ... online today that will appear in the November print issue ... of the JAMA/Archives journals. "Depression in parents is associated ...
Cached Medicine News:Health News:St. Jude researcher receives grant to focus on cancer pharmacogenomics in children 2Health News:TCT 2010 late breaking trials to have impact on practice of interventional cardiology 2Health News:TCT 2010 late breaking trials to have impact on practice of interventional cardiology 3Health News:TCT 2010 late breaking trials to have impact on practice of interventional cardiology 4Health News:What are babies made of? Research shows for some it is sugar, salt and not all things nice 2Health News:Pharmaceutical conservation key to slowing rise of antibiotic-resistant infections 2Health News:Pharmaceutical conservation key to slowing rise of antibiotic-resistant infections 3Health News:Hallucinogen appears safe, may improve mood among patients with advanced-stage cancer and anxiety 2Health News:Parents at highest risk for depression in the first year after child's birth 2
... Offers one-handed operation for stent ... reduce unintentional stent movement. Allows user ... vessel wall apposition. Maintains tactile feel ... ,MicroMarker technology aids in visualization at ...
Vial with 100 Urine Reagent Test Strips, tests for glucose, protein, pH, blood, ketone, bilirubin, nitrite, urobilinogen, specific gravity. FOR LABORATORY USE BY QUALIFIED TECHNICIANS....
... the latest from Quality Mapping Solutions, ... designed specifically for implementing and managing ... superior design, functionality, security, and versatility ... managing a quality program., ,Based upon ...
... Q-Pulse is the UK's market-leading ... over 250 pathology laboratories in the ... Q-Pulse. In addition, hundreds of pathology ... Kong, South Africa and the United ...
Medicine Products: